Loading...
Få $200 for å opprette en Interactive Brokers-konto via lenken vår: Opprett IBKR-konto. Les vår analyse av Interactive Brokers
- Ticker
- AZT.OL
- Price
- 22.00
- Stock movement down
- -1.40 (-6.14%)
- Company name
- Arcticzymes Technologies ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 1.09B
- Ent verdi
- 928.09M
- Pris/omsetning
- 9.70
- Pris/bok
- 3.23
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- 105.72
- Fremtidig P/E
- 30.75
- PEG
- -
- EPS-vekst
- -35.19%
- 1 års avkastning (CAGR)
- 16.81%
- 3 års avkastning (CAGR)
- -18.74%
- 5 års avkastning (CAGR)
- -23.60%
- 10 års avkastning (CAGR)
- 6.74%
Sist oppdatert: 2026-03-09
UTBYTTE
AZT.OL betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | 105.72 |
| Pris til OCF | 22.91 |
| Pris til FCF | 30.06 |
| Pris til EBITDA | 7384.65 |
| EV i forhold til EBITDA | 6270.89 |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 9.70 |
| Pris til bok | 3.23 |
| EV i forhold til salg | 8.24 |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 51.07M |
| EPS (TTM) | 0.20 |
| FCF per aksje (TTM) | 0.71 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 112.62M |
| Bruttofortjeneste (TTM) | 107.93M |
| Driftsinntekter (TTM) | 2.81M |
| Netto inntekt (TTM) | 10.34M |
| EPS (TTM) | 0.20 |
| EPS (1 år fremover) | 0.70 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 95.84% |
| Driftsmargin (TTM) | 2.50% |
| Fortjenestemargin (TTM) | 9.18% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 187.78M |
| Netto fordringer | 21.88M |
| Samlede omløpsmidler | 307.85M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 34.06M |
| Eiendom, anlegg og utstyr | 16.78M |
| Sum eiendeler | 361.41M |
| Leverandørgjeld | 5.00M |
| Kortsiktig/nåværende langsiktig gjeld | 0.00 |
| Sum kortsiktig gjeld | 18.79M |
| Sum gjeld | 22.94M |
| Aksjonærenes egenkapital | 338.47M |
| Netto varige driftsmidler | 0.00 |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | 47.70M |
| Kapitalutgifter (TTM) | 9.85M |
| Fri kontantstrøm (TTM) | 36.35M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | 3.05% |
| Avkastning på eiendeler | 2.86% |
| Avkastning på investert kapital | 3.05% |
| Kontantavkastning på investert kapital | 10.74% |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 22.50 |
| Daglig høy | 22.50 |
| Daglig lav | 21.20 |
| Daglig volum | 47K |
| Tidenes høyeste | 111.00 |
| 1 år analytikerestimat | 32.50 |
| Beta | 0.39 |
| EPS (TTM) | 0.20 |
| Utbytte per aksje | 0.00 |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | 6 May 2026 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| AZT.OL | S&P500 | |
| Nåværende prisfall fra toppnotering | -80.18% | -1.82% |
| Høyeste prisfall | -93.51% | -56.47% |
| Dato for høyeste fall | 21 Dec 2009 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -66.53% | -10.84% |
| Gj.snittlig tid til ny topp | 113 days | 12 days |
| Maks tid til ny topp | 3360 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
1.09B
Markedsverdi kategori
Small-cap
Beskrivelse
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools, such as research and diagnostics, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Ansatte
53
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Norway
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Amid renewed trade and geopolitical uncertainty, the European stock market has seen declines, with the pan-European STOXX Europe 600 Index ending 0.98% lower. Despite these challenges, business activi...
27. januar 2026
As the European market navigates a landscape of mixed economic signals and resilient earnings results, the pan-European STOXX Europe 600 Index has shown modest gains, reflecting cautious optimism amon...
19. januar 2026
Amidst a mixed performance in major European stock indexes, with the STOXX Europe 600 Index ending slightly higher due to resilient economic data and earnings results, investors are keenly observing o...
19. januar 2026
As the European markets experience a wave of optimism with major indexes like the STOXX Europe 600 Index climbing 2.27%, investors are keenly observing opportunities that may be trading below their fa...
13. januar 2026
Amid optimism about the European economy and favorable interest rate conditions, major stock indexes across the region have experienced gains, with Germany's DAX and France's CAC 40 Index showing nota...
13. januar 2026
As the pan-European STOXX Europe 600 Index reaches new highs, buoyed by an improving economic environment and closing 2025 with its strongest yearly performance since 2021, investors are increasingly ...
9. januar 2026
As the European markets continue to flourish, with the STOXX Europe 600 Index reaching new highs and closing out 2025 with its strongest annual performance since 2021, investors are keenly eyeing stoc...
9. januar 2026
As the European markets continue to show strength, with the STOXX Europe 600 Index reaching new highs and closing 2025 with its best performance in years, investors are keenly observing opportunities ...
7. januar 2026
Amidst a buoyant economic environment, the European markets have experienced notable gains, with the STOXX Europe 600 Index reaching new highs and major indices like Germany's DAX and France's CAC 40 ...
7. januar 2026
ArcticZymes Technologies ASA (LTS:0DRV) reports a 24% revenue increase and strategic initiatives for future expansion despite challenges in key markets.
6. november 2025
Neste side